<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01087619</url>
  </required_header>
  <id_info>
    <org_study_id>2010/51</org_study_id>
    <nct_id>NCT01087619</nct_id>
  </id_info>
  <brief_title>Surgery for Primary Hyperparathyroidism (pHPT) in Patients Older Than 65 Years Compared With Follow-up</brief_title>
  <official_title>Primary Hyperparathyroidism in Patients Older Than 65 Years: A Prospective Randomized Trial of Surgical Treatment Compared With Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      General consensus and contemporary guidelines, recommend surgery for primary
      hyperparathyroidism (pHPT)for all patients below the age of 50, for patients with pronounced
      hypercalcemia and for patients with organ complications to the disease (osteoporosis and
      decreased renal function).

      The purpose of this study is to determine if surgery for pHPT, is appropriate for patients
      with moderate to mild hypercalcemia older than 65 years of age.

      The hypothesis of the study is that surgery for pHPT in patients older than 65 years of age,
      and with mild hypercalcemia, will increase bone density and hence decrease future risk for
      fragility fractures compared to patients with follow-up only.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The majority of patients diagnosed and operated due to primary HPT in Scandinavia are older
      than 65 years of age. The vast majority of the patients have mild aberrations of serum
      calcium (&lt; 1.50 mmol/l ionized calcium), and some patients may even be asymptomatic. The
      present trial is designed to clarify the indications for surgical treatment in this large
      subgroup of patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2010</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone density at the hip</measure>
    <time_frame>At two years</time_frame>
    <description>Bone density is assessed with DEXA (dual energy x-ray absorptiometry), at the hip.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone density at the lumbar spine</measure>
    <time_frame>At two years</time_frame>
    <description>Bone density is assessed with DEXA (dual energy x-ray absorptiometry) at the lumber spine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipids</measure>
    <time_frame>At two years</time_frame>
    <description>Triglyceride and cholesterol concentrations of whole serum and of the lipoprotein classes; low-density-lipoprotein (LDL), very-low-density-lipoprotein (VLDL) and high-density-lipoprotein (HDL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function</measure>
    <time_frame>At two years</time_frame>
    <description>Cardiac function assessed with echocardiography; Left ventricular ejection fraction (EF), Left ventricular end-diastolic diameter (LVDD), Left ventricular mass index (LVMI), Ratio between mitral peak velocity flow of the early filling wave and the atrial filling wave (E/A ratio).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>At two years</time_frame>
    <description>Mini Mental State Examination test (MMSE), for cognitive function.
A Quich Test (AQT), for cognitive speed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atherosclerosis</measure>
    <time_frame>At one two years</time_frame>
    <description>Carotid ultrasound/duplex scans with evaluation of intimal-medial thickness and plaques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral glucose tolerance</measure>
    <time_frame>At two years</time_frame>
    <description>Oral glucose tolerance test (75 Gram), with measurement of blood glucose and insulin after 60, 120 and 180 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure (systolic and diastolic)</measure>
    <time_frame>At two years</time_frame>
    <description>24 hours blood pressure measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>At two years</time_frame>
    <description>GFR measured by the clearance of iohexol and urinary albumin excretion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Primary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>Follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients diagnosed biochemically and clinically with primary hyperparathyroidism who are followed only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients diagnosed biochemically and clinically with primary hyperparathyroidism who are treated with parathyroid surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Parathyroid surgery</intervention_name>
    <description>Parathyroid Surgery (regardless of surgical strategy; i.e., focused operation, unilateral- or bilateral neck exploration)</description>
    <arm_group_label>Surgery</arm_group_label>
    <other_name>BA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary Hyperparathyroidism

          -  No previous parathyroid surgery

          -  Sporadic disease

        Exclusion Criteria:

          -  Z-score of Bone density &lt; -2.5 SD (regardless of site)

          -  Serum level of ionized calcium &gt; 1.50 mmol/L

          -  Inability to understand given information or to comply with scheduled follow-up

          -  Symptoms of hypercalcaemia for which specific medical treatment has been prescribed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>66 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders OJ Bergenfelz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skåne University Hospital, Department of Surgery, Lund</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anders OJ Bergenfelz, MD, PhD</last_name>
    <phone>+46 46 172086</phone>
    <email>anders.bergenfelz@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erik Nordenström, MD, PhD</last_name>
    <phone>+46 46 172305</phone>
    <email>erik.nordenstrom@skane.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Skåne University Hospital, Department of Surgery, Lund</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders OJ Bergenfelz, MD, PhD</last_name>
      <phone>+46 46 17 20 86</phone>
      <email>anders.bergenfelz@med.lu.se</email>
    </contact>
    <contact_backup>
      <last_name>Erik Nordenström, MD, PhD</last_name>
      <phone>+46 46 17 23 05</phone>
      <email>erik.nordenstrom@skane.se</email>
    </contact_backup>
    <investigator>
      <last_name>Erik Nordenström, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Almqvist, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2010</study_first_submitted>
  <study_first_submitted_qc>March 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2010</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperparathyroidism, primary</keyword>
  <keyword>Aged 66 years or older</keyword>
  <keyword>Mild hypercalcaemia</keyword>
  <keyword>Surgical Procedures, Elective</keyword>
  <keyword>Indication</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Cognitive function</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Follow-up</keyword>
  <keyword>Randomized trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

